Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
 April 26, 2018 in New York City - EconoTimes)
Geneva, Switzerland and Boston, MA - April 16, 2018- ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that the company will host a key opinion leader (KOL) meeting focused on in vitro fertilization (IVF) Thursday, April 26 from 12:00 to 2:00 p.m. ET in New York City.
The meeting will feature presentations from David Seifer, M.D., Professor of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, and Annette Lee M.D., Medical Director, Toll Center for Reproductive Sciences, Abington Reproductive Medicine. Additionally, members of the ObsEva management team will provide an overview of the company's oral oxytocin receptor antagonist nolasiban, including recently released positive top line results from the Phase 3 IMPLANT2 clinical trial.
A live webcast of the meeting will be accessible under the "Investors" section of ObsEva's website www.obseva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
CEO Office Contact:
Shauna Dillon
[email protected]
+41 22 552 1550
Investor Contact:
Mario Corso
Senior Director, Investor Relations
[email protected]
857-972-9347 office
781-366-5726 mobile
Attachment
